We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Staphylococcus Aureus Avoids Inducing Immune Memory in Model

By LabMedica International staff writers
Posted on 03 Oct 2017
A team of medical microbiologists has identified the mechanism that prevents the body's immune system from developing an effective protective response to repeated Staphylococcus aureus infections.

Investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) sought to clarify why humans do not usually develop effective immunity to Staphylococcus aureus reinfection.

Toward this end, the investigators worked with a mouse model that mimicked human S. More...
aureus infection. They reported in the September 21, 2017, online edition of the journal Cell Host & Microbe that infection by S. aureus caused the immune system to increase production of anti-inflammatory cytokines, specifically interleukin-10 (IL-10), while impairing the anti-pathogenic response from protective Th17 (T helper) cells.

At the mechanistic level they found that O-acetylation of peptidoglycan, a mechanism utilized by S. aureus to block bacterial cell wall breakdown, limited the induction of pro-inflammatory signals required for optimal Th17 polarization. Thus, the bacterial cell wall remained intact after infecting the host, and molecules from the pathogen did not escape to interact with the immune system and trigger the development of robust protective immune memory.

IL-10 deficiency in mice restored protective immunity to S. aureus infection. Using a staphylococcal peptidoglycan O-acetyltransferase mutant as adjuvant reduced IL-10, increased IL-1beta (an important mediator of the inflammatory response), and promoted development of IL-17-dependent, Th cell-transferable protective immunity.

"Essentially, staph tricks the body's T-cells, which are white blood cells that fight infection, and prevents them from mounting an effective defense," said contributing author Dr. Gislaine Martins, assistant professor of biomedical science and medicine at Cedars-Sinai Medical Center. "The study explains why our immune system is fooled by staph. Staph evolved to have this enzyme that makes this modification in its cell wall. This modification protects the wall from degradation and therefore from being properly detected by the immune system, which will not remember the bacteria the next time the body is infected."

Related Links:
Cedars-Sinai Medical Center


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.